Go to deals
Healthcare

Igyxos S.A. has completed a Series A fundraising

Igyxos S.A. has completed a US$8.4 million fundraising as part of a Series A funding led by Bpifrance through its FABS Fund, with participation from the Go Capital Amorçage II and Loire Valley Invest Funds and by the Emergence Innovation II. This will allow the founder Marie Christine Maurel and Professor René Frydman, joined by Pierre-Henry Longeray (ex Merck Serono) as CEO, to pursue the proof of concept in human clinical practice.

Based in Nouzilly, France, biotechnology startup Igyxos is developing a new treatment for female and male infertility that works by shifting hormonal imbalances with a new method using monoclonal antibodies.

Oaklins’ team in France advised Igyxos on a "dual-track" project that allowed them to validate with the industry both scientific and therapeutic interest of its drug candidate based on the use of monoclonal antibodies to improve the treatment of female and male infertility.

Service
Funding, debt advisory & ECM
Parties
“This fundraising of US$8.4 million associated with the arrival of Pierre-Henry Longeray as CEO, and the support and expertise of Professor René Frydman, who has been with us from the beginning, gives us real hope to see the treatment developed by Igyxos successfully reach the market. We thank Oaklins’ team in France for their efficient and strong support.”

Marie-Christine Maurel

CSO and Founder, Igyxos, S.A.

Talk to the deal team

 Jean-Paul  Ortelli

Jean-Paul Ortelli

Senior Advisor

Paris, France
Oaklins France
 Leïla  Djebli

Leïla Djebli

Director

Paris, France
Oaklins France

Related deals

Gilde Healthcare has invested in Tandarts Today
Private Equity | Healthcare

Gilde Healthcare has invested in Tandarts Today

Gilde Healthcare has invested in Tandarts Today, a fast-growing dental chain in the Netherlands. The investment will allow Tandarts Today to accelerate its buy-and-build strategy and become a leading dental chain in the Netherlands. Financial details have not been disclosed.

Learn more
Alcidion (ASX:ALC) has acquired ExtraMed
Healthcare

Alcidion (ASX:ALC) has acquired ExtraMed

Alcidion (ASX:ALC) has acquired ExtraMed Ltd., a UK provider of patient flow management software that helps address key pain-points for hospital administrative staff.

Learn more
Alcidion (ASX:ALC) has completed a capital raise
Healthcare

Alcidion (ASX:ALC) has completed a capital raise

Alcidion (ASX:ALC) has raised funds to continue its growth strategy.

Learn more